European Cystic Fibrosis Society 2023
ECFS 2023 saw the team head to Vienna, Austria to present the study data. Gavin Stone prepared the below poster which showed that Short term changes in adherence to ETI are not reflected in study outcomes at collected at the study visits. This may be because the adherence overall was high. The numbers in this study were small, which shows more research is needed into patient adherence and a more user-friendly device will be need to be developed to do this.
Sharon Sutton, the RECOVER pharmacist analysed data from the combined Treatment Adherence and Adherence Barrier Questionnaire developed specifically for the RECOVER 6-11 cohort. Adherence to Dornase Alpha, enzymes, airway clearance and vitamins reduced from baseline to 9 month. There were no new barriers to adherence seen at baseline compared to 9 months. Data collection will continue for this age group over the coming months.
Gavin Stone prepared a poster looking at antibiotics use prior to and one year after ETI use. There was a significant reduction in participants using both oral and IV antibiotics after starting ETI. Data collection will continue for year two.
Paul McNally presented the study results for the 6-11 cohort. The data showed improvements in lung clearance index, sweat chloride and FEV1. No significant improvements were seen in BMI and the Cystic Fibrosis Revised Questionnaire (CFQR) but this is likely due to a ceiling effect as the participants had normal BMI and CFQR scores prior to starting ETI.
Paul also presented data from baseline and 1 year CT scans in the 12+ age group. The data showed improvements in mucous plugging, bronchial wall thickening and trapped air but no improvements in bronchiectasis. We will see if these improvements are sustained when the 2 years scans are carried out in the coming year.
